Skuteczność drugiej dawki szczepionki RSV (białka 847A i 847B) w zapobieganiu chorobom dolnych dróg oddechowych u dorosłych z osłabioną odpornością

The study focuses on Respiratory syncytial virus infection, a viral illness that can cause serious lung problems, especially in people whose immune system is weakened (immunocompromised). The infection can lead to lower respiratory tract disease, meaning it affects the lungs and the airways that bring air to the lungs.

The vaccine being tested is called Abrysvo. It is given as a shot into the muscle. In the trial some participants receive a second dose of the vaccine after the first dose, while others receive only the initial dose. This comparison is made to see whether an additional dose gives extra protection compared with not receiving a booster.

The purpose of the study is to evaluate how well the vaccine prevents clinically relevant RSV events in immunocompromised adults during the first RSV season after vaccination. Participants are followed for several months, during which they report any respiratory symptoms and attend scheduled health check visits, allowing researchers to record any infections or hospital visits related to the virus.